We are live on ! Find out more
ETON icon

Eton Pharmaceutcials

104 hedge funds and large institutions have $277M invested in Eton Pharmaceutcials in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 28 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

18,130% more call options, than puts

Call options by funds: $1.82M | Put options by funds: $10K

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

1% more funds holding

Funds holding: 103104 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6.65% less ownership

Funds ownership: 67.83%61.18% (-6.7%)

24% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 37

30% less capital invested

Capital invested by funds: $398M → $277M (-$121M)

Holders
104
Holders Change
+1
Holders Change %
+0.97%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
21
Increased
28
Reduced
37
Closed
19
Calls
$1.82M
Puts
$10K
Net Calls
+$1.81M
Net Calls Change
-$340K
Name Holding Trade Value Shares
Change
Change in
Stake
WP
26
Woodline Partners
California
$1.61M +$1.68M +95,487 New
BCM
27
Bridgeway Capital Management
Texas
$1.42M -$440K -25,000 -23%
Wellington Management Group
28
Wellington Management Group
Massachusetts
$1.37M -$123K -7,018 -8%
Millennium Management
29
Millennium Management
New York
$1.34M +$1.12M +63,469 +400%
Charles Schwab
30
Charles Schwab
California
$1.31M -$1.09K -62 -0.1%
Two Sigma Investments
31
Two Sigma Investments
New York
$1.3M -$3.69M -209,819 -73%
Connor, Clark & Lunn Investment Management (CC&L)
32
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.3M -$1.18M -67,225 -47%
Citadel Advisors
33
Citadel Advisors
Florida
$1.25M +$1.3M +74,144 New
N
34
Nuveen
North Carolina
$996K
Jane Street
35
Jane Street
New York
$982K -$227K -12,888 -18%
Barclays
36
Barclays
United Kingdom
$870K +$258K +14,642 +40%
Russell Investments Group
37
Russell Investments Group
United Kingdom
$840K -$91K -5,171 -9%
PCM
38
Prelude Capital Management
New York
$766K +$60.7K +3,452 +8%
ACA
39
Anchor Capital Advisors
Massachusetts
$688K +$68.5K +3,890 +11%
XT
40
XTX Topco
Cayman Islands
$550K +$143K +8,128 +33%
William Blair & Company
41
William Blair & Company
Illinois
$548K
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$515K -$100K -5,688 -16%
Wells Fargo
43
Wells Fargo
California
$478K +$204K +11,584 +69%
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$416K +$433K +24,615 New
GC
45
Guilbault Capital
Louisiana
$393K +$409K +23,225 New
ACM
46
Aquatic Capital Management
Illinois
$386K -$238K -13,530 -37%
EIM
47
Essex Investment Management
Massachusetts
$341K
Invesco
48
Invesco
Georgia
$333K +$109K +6,213 +46%
JWS
49
Juncture Wealth Strategies
Arizona
$321K +$35.7K +2,028 +12%
BCC
50
Bridge City Capital
Oregon
$315K +$33.9K +1,927 +12%

ETON Hedge Fund Activity: Q4 2025 in Review

104 of the 8,239 institutional investors tracked by Wall St. Rank reported a position in Eton Pharmaceutcials (ETON) for Q4 2025, worth a combined $277M — down 30% from $398M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ETON positions and 19 closed out — a net gain of 2 holders — while 28 added to existing stakes and 37 trimmed.

The largest buyer was Oberweis Asset Management, adding an estimated $4.2M. The largest seller was Royal Bank of Canada, cutting an estimated $8.41M.

  • 104 institutional investors held Eton Pharmaceutcials (ETON) as of Q4 2025, up from 103 in Q3 2025.
  • Funds reported $277M of Eton Pharmaceutcials stock for Q4 2025, down 30% quarter-over-quarter.
  • 21 funds opened new Eton Pharmaceutcials positions in Q4 2025 and 19 closed out, a net change of +2 holders.
  • The largest Eton Pharmaceutcials buyer in Q4 2025 was Oberweis Asset Management, an estimated $4.2M added.
  • The largest Eton Pharmaceutcials seller in Q4 2025 was Royal Bank of Canada, an estimated $8.41M sold.

Based on aggregated 13F filings for Q4 2025.